You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | -2,654.2% | 0.0% |
| ROCE | 0.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | -9.0 | 0.0 |
| PEG | 0.0 | -999,999.0 |
| Price / Revenue | 270.1 | 7.5 |
| Price / Book value | 4.8 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 14.3% | -23.3% |
| PBT | 0.0% | n/a |
| EPS | 0.0% | 277.2% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2015-05-31 | 1.34 | -2.01 | -8.67p | 0.0 | 0.0 | n/a | n/a | 0.0% |
| 2016-05-31 | 0.43 | -9.01 | -12.97p | -10.1 | 0.0 | n/a | n/a | 0.0% |
| 2017-05-31 | 0.21 | -5.32 | -9.84p | -14.3 | 0.0 | n/a | n/a | 0.0% |
| 2018-05-31 | 0.24 | -6.34 | -11.41p | -11.1 | 0.0 | n/a | n/a | 0.0% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2019-05-31 | 1.50 | 0.00 | -15.60p | 0.0 | n/a | 0% | 0.00p | 0.0% |
| 2020-05-31 | 8.60 | 0.00 | -8.00p | 0.0 | n/a | 0% | 0.00p | 0.0% |
| 2021-05-31 | 19.20 | 0.00 | 5.70p | 18.0 | n/a | 0% | 0.00p | 0.0% |
| Oncimmune partners with R-Pharm to take 'EarlyCDT Lung' to Russia Sharecast News | 04 Jul |
|---|---|
| Oncimmune sells US operations to and partners with Biodesix Sharecast News | 28 Jun |
| Oncimmune confident of 'material profitable revenues' Sharecast News | 26 Jun |
| Commercialisation Partnership in Russia | 04-Jul-19 10:39 |
|---|---|
| Commercialisation Agreement in US with Biodesix | 28-Jun-19 07:07 |
| Business Update | 26-Jun-19 07:05 |
| Positive Results for Early Cancer Detection Test | 04-Jun-19 07:04 |
| Regulatory Approval in Israel for EarlyCDT®-Lung | 15-May-19 07:05 |